<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545454</url>
  </required_header>
  <id_info>
    <org_study_id>ACT5488</org_study_id>
    <secondary_id>EudraCT 2007-00760-24</secondary_id>
    <nct_id>NCT00545454</nct_id>
  </id_info>
  <brief_title>Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis</brief_title>
  <acronym>ACCORD-RA</acronym>
  <official_title>Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis (RA): A 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of 90 µg Administered Once Daily and 90 µg Once Every Other Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the reduction of systemic inflammation as
      measured by serum levels of C-reactive protein (CRP).

      The secondary objectives are:

        -  to assess the reduction of systemic inflammation as measured changes in acute phase
           protein, serum amyloid A (SAA) and cytokine interleukin-6 (IL-6), and clinical American
           College of Rheumatology response rate, and morning stiffness duration;

        -  to assess the effect on pain relief within first 14 days;

        -  to obtain evidence of the safety and tolerability of SSR150106;

        -  to document trough plasma levels of SSR150106 and its first metabolite.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean C-Reactive Protein level</measure>
    <time_frame>end of the 4-week double-blind treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein, Serum Amyloid A and Cytokine Interleukin-6 levels</measure>
    <time_frame>at all time points measured</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement responder rates based on the American College of Rheumatology criteria</measure>
    <time_frame>at all time points measured</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief (change from baseline)</measure>
    <time_frame>until day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>During the entire study patient's participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of SSR150106 and its first metabolite</measure>
    <time_frame>On a weekly basis during treatment phase, except at the end of the 3rd week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SSR150106 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 micro grams oral solution once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSR150106 OEQD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 micro grams oral solution once every other day (OEQD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral solution QD or OEQD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSR150106</intervention_name>
    <arm_group_label>SSR150106 QD</arm_group_label>
    <arm_group_label>SSR150106 OEQD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either treatment-naïve patients, or those who have discontinued their Rheumatoid
             Arthritis-directed medication due to intolerability or insufficient efficacy

          -  At least 9 out of 68 tender joints; 6 out of 66 swollen joints; morning stiffness 45
             min

          -  C-Reactive Protein &gt;=1.8 mg/dl confirmed during screening period

          -  Non-poor Cytochrome P2D6 metabolizer status

        Exclusion Criteria:

          -  Functional Rheumatoid Arthritis class IV

          -  Fever

          -  Infections with hepatitis B, or C, or HIV

          -  Presence or history (&lt;5 years) of cancer

          -  Manifest or latent tuberculosis

          -  Functional abnormalities (including laboratory values) judged as clinically relevant

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karel PAVELKA, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karel PAVELKA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <disposition_first_submitted>August 4, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 4, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>anti-cytokine</keyword>
  <keyword>anti-chemokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

